title: Drug-loaded PLGA-mPEG microparticles as treatment for atopic dermatitis-like skin lesions in BALB/c mice model.
abstract: This study evaluated the feasibility of mizolastine-loaded microparticles as therapy for atopic dermatitis. Microparticles have been researched for decades as a controlled-release drug delivery system, but seldom been used as treatment for skin disease. In this research, we induced dermatitis in BALB/c mice model by repeated topical application of dinitrofluorobenzene and compared the mizolastine microparticles injection and daily mizolastine injection treatment. The results showed that the mizolastine microparticles treatments significantly inhibited ear thickness and dermatitis index in dermatitis model compared with the dermatitis mice without treatment, showing a similar curative effect compared with daily mizolastine injection treatment, and the improvement continued for several days. Inflammatory cells infiltration into the ears and the plasma level of immunoglobulin E were also suppressed by mizolastine microparticles according to the histopathology analysis. In conclusion, the results suggested that drug-loaded microparticles could be a proper candidate for the treatment of skin diseases.
authors.affiliation: State Key Laboratory of Material Processing and Die & Mould Technology, College of Materials Science and Engineering, Huazhong University of Science and Technology (HUST) , Wuhan , PR China.
authors.forename: Shuibin
authors.initials: S
authors.lastname: Feng
authors.forename: Lei
authors.initials: L
authors.lastname: Nie
authors.forename: Peng
authors.initials: P
authors.lastname: Zou
authors.forename: Jinping
authors.initials: J
authors.lastname: Suo
mesh_terms: D000287:Administration, Topical; D000818:Animals; D001562:Benzimidazoles / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D003876:Dermatitis, Atopic / Q000139:chemically induced / Q000188:drug therapy; D004139:Dinitrofluorobenzene / Q000633:toxicity*; D004195:Disease Models, Animal; D004337:Drug Carriers / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D019344:Lactic Acid / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D011092:Polyethylene Glycols / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D011100:Polyglycolic Acid / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer
chemical_list: D001562:Benzimidazoles; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; C076170:mizolastine; D011100:Polyglycolic Acid; D019344:Lactic Acid; D011092:Polyethylene Glycols; D004139:Dinitrofluorobenzene; C000595209:polyethylene glycol 1000
keywords: Biomaterial; controlled release; dermatitis; microspheres